{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T09:38:45Z","timestamp":1773221925854,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Science and Technology Innovation Action Plan of Shanghai","award":["21YF1406300"],"award-info":[{"award-number":["21YF1406300"]}]},{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai Municipality","doi-asserted-by":"publisher","award":["22ZR1411400"],"award-info":[{"award-number":["22ZR1411400"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04603-2","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T08:08:10Z","timestamp":1770365290000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune heterogeneity at diagnosis influences treatment response and survival in multiple myeloma"],"prefix":"10.1007","volume":"17","author":[{"given":"Yue","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianwei","family":"Lan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyang","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"issue":"10272","key":"4603_CR1","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410\u201327.","journal-title":"Lancet"},{"issue":"2","key":"4603_CR2","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet Therapy, Transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022;387(2):132\u201347.","journal-title":"N Engl J Med"},{"issue":"1","key":"4603_CR3","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41408-024-01172-x","volume":"14","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Sun F, Alapat DV, Wanchai V, Mery D, Siegel ER, et al. Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages. Blood Cancer J. 2024;14(1):194.","journal-title":"Blood Cancer J"},{"issue":"10","key":"4603_CR4","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1158\/2767-9764.CRC-22-0022","volume":"2","author":"L Yao","year":"2022","unstructured":"Yao L, Jayasinghe RG, Lee BH, Bhasin SS, Pilcher W, Doxie DB, et al. Comprehensive characterization of the multiple myeloma immune microenvironment using integrated scRNA-seq, CyTOF, and CITE-seq analysis. Cancer Res Commun. 2022;2(10):1255\u201365.","journal-title":"Cancer Res Commun"},{"key":"4603_CR5","doi-asserted-by":"publisher","first-page":"1102471","DOI":"10.3389\/fimmu.2022.1102471","volume":"13","author":"C Giannotta","year":"2022","unstructured":"Giannotta C, Autino F, Massaia M. The immune suppressive tumor microenvironment in multiple myeloma: the contribution of myeloid-derived suppressor cells. Front Immunol. 2022;13:1102471.","journal-title":"Front Immunol"},{"issue":"22","key":"4603_CR6","doi-asserted-by":"publisher","first-page":"5873","DOI":"10.1182\/bloodadvances.2022007217","volume":"6","author":"C Schinke","year":"2022","unstructured":"Schinke C, Poos AM, Bauer M, John L, Johnson S, Deshpande S, et al. Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level. Blood Adv. 2022;6(22):5873\u201383.","journal-title":"Blood Adv"},{"key":"4603_CR7","doi-asserted-by":"publisher","first-page":"1271807","DOI":"10.3389\/fonc.2023.1271807","volume":"13","author":"R Prabhala","year":"2023","unstructured":"Prabhala R, Pierceall WE, Samur M, Potluri LB, Hong K, Peluso T, et al. Immunomodulation of NK, NKT and B\/T cell subtypes in relapsed\/refractory multiple myeloma patients treated with Pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival. Front Oncol. 2023;13:1271807.","journal-title":"Front Oncol"},{"issue":"2","key":"4603_CR8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.21873\/cdp.10293","volume":"4","author":"K Suzuki","year":"2024","unstructured":"Suzuki K, Matsumoto M, Hiramatsu Y, Takezako N, Tamai Y, Suzuki K. NK and T-lymphocyte kinetics predict outcome in myeloma patients treated with Elotuzumab, Lenalidomide plus dexamethasone. Cancer Diagn Progn. 2024;4(2):97\u2013104.","journal-title":"Cancer Diagn Progn"},{"key":"4603_CR9","doi-asserted-by":"crossref","unstructured":"Duffy AM, Goenka A, Azeem MI, Taz A, Potdar SV, Scott SA et al. Early CD4\u2009+\u2009T-cell proliferative burst and chronic T-cell engagement impact myeloma outcomes following T-cell engager therapy. J Clin Invest. 2025.","DOI":"10.1172\/JCI192927"},{"key":"4603_CR10","doi-asserted-by":"crossref","unstructured":"Bruins WSC, Smits F, Duetz C, Groen K, Korst C, de Jonge, AVd et al. A T-cell-based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapy. Blood. 2025.","DOI":"10.1182\/blood.2025028587"},{"issue":"26","key":"4603_CR11","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: A report from international myeloma working group. J Clin Oncol. 2015;33(26):2863\u20139.","journal-title":"J Clin Oncol"},{"issue":"29","key":"4603_CR12","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","volume":"40","author":"M D\u2019Agostino","year":"2022","unstructured":"D\u2019Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: A European myeloma network (EMN) report within the HARMONY project. J Clin Oncol. 2022;40(29):3406\u201318.","journal-title":"J Clin Oncol"},{"issue":"8","key":"4603_CR13","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0145-2126(01)00192-8","volume":"26","author":"M Koike","year":"2002","unstructured":"Koike M, Sekigawa I, Okada M, Matsumoto M, Iida N, Hashimoto H, et al. Relationship between CD4(+)\/CD8(+) T cell ratio and T cell activation in multiple myeloma: reference to IL-16. Leuk Res. 2002;26(8):705\u201311.","journal-title":"Leuk Res"},{"issue":"2","key":"4603_CR14","doi-asserted-by":"publisher","first-page":"e202451191","DOI":"10.1002\/eji.202451191","volume":"55","author":"M Villard","year":"2025","unstructured":"Villard M, Viel S, Karlin L, Avet-Loiseau H, Martinet L, Marcais A, et al. NK cell immaturity and NKp30 expression positively correlate with clinical outcome in multiple myeloma patients from the IFM2009 clinical trial. Eur J Immunol. 2025;55(2):e202451191.","journal-title":"Eur J Immunol"},{"key":"4603_CR15","doi-asserted-by":"crossref","unstructured":"Hasanali ZS, Garfall AL, Burzenski L, Shultz LD, Tang Y, Kadu S et al. Human IL-6 fosters long-term engraftment of patient-derived disease-driving myeloma cells in immunodeficient mice. JCI Insight. 2024;9(10).","DOI":"10.1172\/jci.insight.177300"},{"issue":"8","key":"4603_CR16","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/ajh.27327","volume":"99","author":"MJ Rees","year":"2024","unstructured":"Rees MJ, Kumar S. High-risk multiple myeloma: redefining genetic, clinical, and functional high-risk disease in the era of molecular medicine and immunotherapy. Am J Hematol. 2024;99(8):1560\u201375.","journal-title":"Am J Hematol"},{"issue":"3","key":"4603_CR17","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/s41591-022-02178-3","volume":"29","author":"M Larrayoz","year":"2023","unstructured":"Larrayoz M, Garcia-Barchino MJ, Celay J, Etxebeste A, Jimenez M, Perez C, et al. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma. Nat Med. 2023;29(3):632\u201345.","journal-title":"Nat Med"},{"issue":"6","key":"4603_CR18","doi-asserted-by":"publisher","first-page":"101584","DOI":"10.1016\/j.xcrm.2024.101584","volume":"5","author":"O Van Oekelen","year":"2024","unstructured":"Van Oekelen O, Amatangelo M, Guo M, Upadhyaya B, Cribbs AP, Kelly G, et al. Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed\/refractory multiple myeloma. Cell Rep Med. 2024;5(6):101584.","journal-title":"Cell Rep Med"},{"key":"4603_CR19","doi-asserted-by":"publisher","first-page":"1078725","DOI":"10.3389\/fonc.2023.1078725","volume":"13","author":"L John","year":"2023","unstructured":"John L, Miah K, Benner A, Mai EK, Kriegsmann K, Hundemer M, et al. Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed\/refractory multiple myeloma. Front Oncol. 2023;13:1078725.","journal-title":"Front Oncol"},{"issue":"3","key":"4603_CR20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3343\/alm.2021.41.3.259","volume":"41","author":"MY Lee","year":"2021","unstructured":"Lee MY, Park CJ, Cho YU, You E, Jang S, Seo EJ, et al. Immune checkpoint programmed cell death Protein-1 (PD-1) expression on bone marrow T cell subsets in patients with plasma cell myeloma. Ann Lab Med. 2021;41(3):259\u201367.","journal-title":"Ann Lab Med"},{"issue":"1","key":"4603_CR21","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1182\/blood.V90.1.340.340_340_345","volume":"90","author":"NE Kay","year":"1997","unstructured":"Kay NE, Leong T, Kyle RA, Greipp P, Billadeau D, Van Ness B, et al. Circulating blood B cells in multiple myeloma: analysis and relationship to Circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern cooperative oncology group phase III E9486 clinical trial. Blood. 1997;90(1):340\u20135.","journal-title":"Blood"},{"key":"4603_CR22","doi-asserted-by":"publisher","first-page":"663748","DOI":"10.3389\/fimmu.2021.663748","volume":"12","author":"L Zhaoyun","year":"2021","unstructured":"Zhaoyun L, Rong F. Predictive role of immune profiling for survival of multiple myeloma patients. Front Immunol. 2021;12:663748.","journal-title":"Front Immunol"},{"key":"4603_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.leukres.2016.08.008","volume":"49","author":"F Pojero","year":"2016","unstructured":"Pojero F, Casuccio A, Giambanco C, Bulati M, Buffa S, Di Bassiano F, et al. Bone marrow B lymphocytes in multiple myeloma and MGUS: focus on distribution of Naive cells and memory subsets. Leuk Res. 2016;49:51\u20139.","journal-title":"Leuk Res"},{"issue":"12","key":"4603_CR24","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1182\/blood.2023023529","volume":"144","author":"E Blanquart","year":"2024","unstructured":"Blanquart E, Ekren R, Rigaud B, Joubert MV, Baylot V, Daunes H, et al. NK cells with adhesion defects and reduced cytotoxic functions are associated with a poor prognosis in multiple myeloma. Blood. 2024;144(12):1271\u201383.","journal-title":"Blood"},{"issue":"4","key":"4603_CR25","doi-asserted-by":"publisher","first-page":"e306","DOI":"10.1038\/bcj.2015.32","volume":"5","author":"T Dosani","year":"2015","unstructured":"Dosani T, Carlsten M, Maric I, Landgren O. The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies. Blood Cancer J. 2015;5(4):e306.","journal-title":"Blood Cancer J"},{"issue":"1","key":"4603_CR26","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1038\/s41467-021-22804-x","volume":"12","author":"R Liu","year":"2021","unstructured":"Liu R, Gao Q, Foltz SM, Fowles JS, Yao L, Wang JT, et al. Co-evolution of tumor and immune cells during progression of multiple myeloma. Nat Commun. 2021;12(1):2559.","journal-title":"Nat Commun"},{"issue":"14","key":"4603_CR27","doi-asserted-by":"publisher","first-page":"e70019","DOI":"10.1002\/cam4.70019","volume":"13","author":"T Tachita","year":"2024","unstructured":"Tachita T, Ri M, Aoki S, Asano A, Kanamori T, Totani H, et al. Comprehensive analysis of serum cytokines in patients with multiple myeloma before and after Lenalidomide and dexamethasone. Cancer Med. 2024;13(14):e70019.","journal-title":"Cancer Med"},{"key":"4603_CR28","doi-asserted-by":"crossref","unstructured":"Mielnik M, Szudy-Szczyrek A, Homa-Mlak I, Mlak R, Podgajna-Mielnik M, Goracy A et al. The clinical relevance of selected cytokines in newly diagnosed multiple myeloma patients. Biomedicines. 2023;11(11).","DOI":"10.3390\/biomedicines11113012"},{"key":"4603_CR29","doi-asserted-by":"publisher","first-page":"1852517","DOI":"10.1155\/2017\/1852517","volume":"2017","author":"C Musolino","year":"2017","unstructured":"Musolino C, Allegra A, Innao V, Allegra AG, Pioggia G, Gangemi S. Inflammatory and Anti-Inflammatory Equilibrium, proliferative and antiproliferative balance: the role of cytokines in multiple myeloma. Mediators Inflamm. 2017;2017:1852517.","journal-title":"Mediators Inflamm"},{"issue":"2","key":"4603_CR30","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/leu.2015.259","volume":"30","author":"BD Palma","year":"2016","unstructured":"Palma BD, Guasco D, Pedrazzoni M, Bolzoni M, Accardi F, Costa F, et al. Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: role of chemokine (C-C motif) ligand 20. Leukemia. 2016;30(2):409\u201316.","journal-title":"Leukemia"},{"issue":"3","key":"4603_CR31","doi-asserted-by":"publisher","first-page":"721","DOI":"10.20892\/j.issn.2095-3941.2020.0430","volume":"18","author":"F Jiang","year":"2021","unstructured":"Jiang F, Liu H, Peng F, Liu Z, Ding K, Song J, et al. Complement C3a activates osteoclasts by regulating the PI3K\/PDK1\/SGK3 pathway in patients with multiple myeloma. Cancer Biol Med. 2021;18(3):721\u201333.","journal-title":"Cancer Biol Med"},{"issue":"1","key":"4603_CR32","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/s12967-025-06319-3","volume":"23","author":"F Jiang","year":"2025","unstructured":"Jiang F, Zhang Y, Peng F, Liu H, Ding K, Cao P, et al. Complement C3a promotes the formation of osteoclasts by inhibiting Sirt1 to activate the PI3K\/PDK1\/SGK3 pathway in patients with multiple myeloma. J Transl Med. 2025;23(1):338.","journal-title":"J Transl Med"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04603-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04603-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04603-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T12:22:32Z","timestamp":1773145352000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04603-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4603"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04603-2","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"5 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Ethics Committee of Zhongshan Hospital, Fudan University (Approval No. B2017-031R). Written informed consent was obtained from all patients prior to participation, permitting the use of their clinical and laboratory data for research purposes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"405"}}